Stockreport

Alumis Announces Positive Phase 1 Data for CNS Penetrant TYK2 Inhibitor, A-005 [Yahoo! Finance]

Alumis Inc.  (ALMS) 
PDF – Maximal TYK2 inhibition achieved with favorable pharmacokinetic profile in CNS and periphery – – Data support advancement to Phase 2 clinical trial in multiple scle [Read more]